Morgan Stanley vs Tilray Brands Inc — how do they compare? Morgan Stanley trades at $190.02 (market cap $294.39B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Morgan Stanley is far larger — about 554.9× Tilray Brands Inc's market cap, and Morgan Stanley pays a 2.45% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 92 Days and Tilray Brands Inc for 31 Days on average.
| MS | TLRY | |
|---|---|---|
Market Cap | $294.39B | $530.54M |
Volume | 5,836,423 | 9,099,075 |
Sector | Financials | Health |
52-Week High | $228.42 | $21.00 |
52-Week Low | $151.86 | $3.57 |
Typical Hold Time | 92 Days | 31 Days |
Enterprise Value | $660.04B | $684.46M |
Dividend Yield | 2.45% | — |
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $189.71, down 0.66% with bearish technical signals despite strong fundamentals. The company has delivered three consecutive earnings beats with Q2 2026 EPS of $3.46 beating expectations by $0.57. Revenue growth accelerated to $66.0 billion in 2025 with net income margin expanding to 27.59%. Analyst consensus remains bullish with 55.77% buy ratings and a $229.25 price target representing 21% upside potential.
The investment case balances strong profitability and growth opportunities in wealth management and AI financing against concerning cash flow trends and technical weakness. While valuation appears reasonable at 15.14 P/E, investors face risks from volatile operating cash flows and rising debt levels. The stock offers attractive upside to analyst targets but requires monitoring of capital markets recovery timing.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →